Latest Infant Milk Formula News

Bubs Australia Limited reports a strong FY25 with 29% revenue growth to $102.5 million, positive EBITDA turnaround, and sustained cash flow improvements. The company also advances its US market ambitions with a key FDA submission underway.

Bubs Australia has submitted critical clinical trial data to the US FDA, marking a pivotal step toward permanent approval for its infant formulas in the US market.

The a2 Milk Company posted robust first-half FY25 results, lifting revenue by 10.1% and net profit by 7.6%, while introducing a dividend policy for the first time. Strong English label IMF sales and liquid milk growth underpin an upgraded full-year outlook.

The a2 Milk Company delivered solid first-half FY25 results with revenue up 10.1% and net profit rising 7.6%, driven by strong growth in China and the USA despite supply constraints and ANZ challenges. The company also declared its first-ever interim dividend and upgraded its full-year outlook.

The a2 Milk Company has reported robust first-half FY25 results, boosting full-year guidance and declaring its inaugural dividend, underscoring confidence in its growth trajectory.

Bubs Australia has reported a strong Q2 FY25 performance with a positive EBITDA turnaround and robust revenue growth, while advancing its critical FDA clinical trial in the US.